Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
David Scadden
Dana Farber Cancer Inst, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Agios Pharmaceuticals
Equity Interest - Publicly traded entity (e.g., stock, stock option, or other ownership interest)
Please see attached
Evolution and Treatment Response of Brain, Breast, and Hematologic Malignancies
The Dana-Farber Cancer Institute-Physical Sciences-Oncology Center (DFCI-PSOC) will bring together a trans-disciplinary research team to advance our understanding of the physical principles that govern the response of tumor cell populations to treatment and the emergence of resistance. We will identify best treatment modalities based on single cell profiling of the physical parameters of cells for hematologic, brain and breast malignancies, and disseminate our methodologies and findings to the scientific community and general public. Average Scores of the Components: Overall: 2.0 Project 1: 2.1 Project 2: 1.9 Project 3: 2.0 Resource Core 1: 2.0 Education and Outreach: 2.4
Filed on January 10, 2019.
Tell us what you know about David Scadden's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “David Scadden”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| David Scadden | University of Tx Md Anderson Can Ctr | Conflict of Interest | Fate Therapeutics | Value cannot be readily determined |
| David Scadden | Harvard University | Conflict of Interest | Magenta Therapeutic | >$600,000 |
| David Scadden | Dana Farber Cancer Inst | Conflict of Interest | Agios Pharmaceuticals | $40,000 - $59,999 |
| David Scadden | University of Tx Md Anderson Can Ctr | Conflict of Interest | Fate Therapeutics | $5,000 - $9,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.